Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

Oct 19, 2020 7:00am EDT

Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 15, 2020 7:30am EDT

Aptose to Present at September Investor Conferences

Sep 09, 2020 7:30am EDT

Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference

Aug 06, 2020 7:30am EDT

Aptose Reports Results for the Second Quarter 2020

Aug 04, 2020 4:01pm EDT

Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020

Jul 21, 2020 4:01pm EDT

Aptose Announces Pricing of Public Offering of Common Shares

Jul 15, 2020 10:49pm EDT

Aptose Announces Proposed Public Offering of Common Shares

Jul 15, 2020 4:01pm EDT

Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia

Jun 29, 2020 7:01am EDT

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Jun 12, 2020 7:00am EDT